Should I buy or sell Prenetics Global stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRE shares. View PRE analyst ratings or view top-rated stocks .

What is Prenetics Global's stock price target for 2024?

1 Wall Street analysts have issued 1-year target prices for Prenetics Global's shares. Their PRE share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price. View analysts price targets for PRE or view top-rated stocks among Wall Street analysts .

How have PRE shares performed in 2023?

Prenetics Global's stock was trading at $30.00 at the beginning of 2023. Since then, PRE shares have decreased by 86.0% and is now trading at $4.20. View the best growth stocks for 2023 here .

Are investors shorting Prenetics Global?

Prenetics Global saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 31,600 shares, a decline of 87.1% from the October 31st total of 245,600 shares. Based on an average daily trading volume, of 6,300 shares, the days-to-cover ratio is presently 5.0 days. Approximately 0.5% of the company's shares are sold short. View Prenetics Global's Short Interest .

When is Prenetics Global's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our PRE earnings forecast .

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) announced its quarterly earnings data on Friday, September, 15th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.15. The firm had revenue of $5.70 million for the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 3.89% and a negative net margin of 55.31%.

When did Prenetics Global's stock split?

Shares of Prenetics Global reverse split before market open on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Prenetics Global's major shareholders?

Prenetics Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Prudential PLC (7.50%).

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Prenetics Global Stock Price, News & Analysis (NASDAQ:PRE)

$4.20

-0.03 (-0.71%)

(As of 11/30/2023 ET)

Compare

Today's Range: $4.10
▼
$4.20
50-Day Range: $0.36
▼
$7.28
52-Week Range: $3.84
▼
$46.05

Volume: 15,096 shs
Average Volume: 23,392 shs
Market Capitalization: $38.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.00

Prenetics Global MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,328.6% Upside
$60.00 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.20) to $0.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

316th out of 949 stocks

Holding & Other Investment Offices Industry

1st out of 7 stocks

3.5

Analyst's Opinion

Consensus Rating
Prenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.00, Prenetics Global has a forecasted upside of 1,328.6% from its current price of $4.20.
Amount of Analyst Coverage
Prenetics Global has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Prenetics Global has been sold short.
Short Interest Ratio / Days to Cover
Prenetics Global has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Prenetics Global has recently decreased by 87.13%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Prenetics Global does not currently pay a dividend.
Dividend Growth
Prenetics Global does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRE.

3.6

News and Social Media Coverage

News Sentiment
Prenetics Global has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Prenetics Global this week, compared to 1 article on an average week.
Search Interest
2 people have searched for PRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prenetics Global insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Prenetics Global is held by insiders.
Percentage Held by Institutions
Only 39.14% of the stock of Prenetics Global is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Prenetics Global are expected to grow in the coming year, from ($4.20) to $0.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prenetics Global is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prenetics Global is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prenetics Global has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prenetics Global Stock (NASDAQ:PRE)

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

PRE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRE Stock News Headlines

November 20, 2023 | benzinga.com

Prenetics Global Stock (NASDAQ:PRE) Insider Trades

November 20, 2023 | msn.com

Prenetics Global GAAP EPS of -$0.08, revenue of $4.86M

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 20, 2023 | benzinga.com

Prenetics Global: Q3 Earnings Insights

November 20, 2023 | finance.yahoo.com

Prenetics Announces Third Quarter 2023 Financial Results

November 11, 2023 | finance.yahoo.com

Prenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?

November 5, 2023 | morningstar.com

Prenetics Global Ltd Class A PRE

November 1, 2023 | msn.com

Prenetics Global announces reverse stock split

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 1, 2023 | finance.yahoo.com

Prenetics Global Limited Announces Reverse Stock Split

October 30, 2023 | money.usnews.com

Prenetics Global Limited - Ordinary Shares - Class A

October 3, 2023 | finance.yahoo.com

Genetic Genealogy Market | Direct-To-Customer Segment Registered The Highest Growth - Here's Why

September 15, 2023 | finanznachrichten.de

Prenetics Global Limited: Prenetics Announces Second Quarter 2023 Financial Results

September 15, 2023 | finance.yahoo.com

Prenetics Announces Second Quarter 2023 Financial Results

September 10, 2023 | finance.yahoo.com

PRE - Prenetics Global Limited

August 29, 2023 | finance.yahoo.com

A World's First: The Miss Hong Kong Pageant 2023 Unveiled Contestants' CircleDNA Results Live on Television

July 22, 2023 | fool.com

Prenetics Global (NASDAQ: PRE)

July 16, 2023 | finance.yahoo.com

Prenetics Global (NASDAQ:PRE) investors are sitting on a loss of 78% if they invested a year ago

July 4, 2023 | msn.com

Ex-Fave boss Joel Neoh takes on yet another role, co-creates a founder-led early-stage VC

June 30, 2023 | finance.yahoo.com

Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

June 29, 2023 | proactiveinvestors.com

Prenetics Global signs "transformational" $200mln deal to...Prenetics Global signs "transformational" $200mln deal to create...

June 26, 2023 | msn.com

Prenetics Global Limited (PRE) Is Considered a Good Investment by Brokers: Is That True?

June 26, 2023 | finance.yahoo.com

Prenetics Announces $200M JV with Prof. Dennis Lo for Multi-Cancer Early Detection Screening

June 25, 2023 | msn.com

EXCLUSIVE: Prenetics, Professor Dennis Lo Aim To Make Early Cancer Detection 'Universally Accessible Necessity' With $200M Joint Venture

June 25, 2023 | finance.yahoo.com

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening

June 17, 2023 | es-us.finanzas.yahoo.com

Colorectal Cancer Screening Global Market to 2033: Earlier Cancer Detection Enables Reduced Treatment Costs Fuelling Growth

June 16, 2023 | msn.com

With 2 new roles created for him, ex-Fave CEO Joel Neoh opens up on why he joined CircleDNA

See More Headlines

Receive PRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 9/15/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Holding & other investment offices
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRE
CUSIP: N/A
CIK: 1876431
Web: www.prenetics.com
Phone: 852-2210-9588
Fax: N/A
Employees: 400
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.00
High Stock Price Target: $60.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +1,328.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-190,450,000.00
Net Margins: -55.31%
Pretax Margin: -29.55%
Return on Equity: -3.89%
Return on Assets: -3.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.61
Quick Ratio: 2.53

Sales & Book Value

Annual Sales: $279.64 million
Price / Sales: 0.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $25.04 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 9,137,000
Free Float: 8,424,000
Market Cap: $38.38 million
Optionable: Not Optionable
Beta: -0.36

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Sheng Wu Yeung (Age 44)
Co-Founder, Chairperson, CEO & CEO of Insighta
Dr. Chi Hung Tzang Ph.D. (Age 48)
Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
Mr. Hoi Chun Lo (Age 38)
Chief Financial Officer
Dr. Yung Ho Wong DPHIL (Age 41)
Chief Technology Officer
Ms. Yvonne L. Wong
Chief Corporate Development Officer
Ms. Samantha Kwok
Vice President People & Culture
Dr. Senthil Sundaram M.D. (Age 49)
Chief Clinical Officer
Mr. Avrom Boris Lasarow (Age 46)
Chief Executive Officer of EMEA
Dr. Shih-Chang Ong M.D. (Age 45)
Chief Medical Officer & Member of Scientific Advisory Board
Mr. Joel Neoh
Chief Consumer Officer & MD for CircleDNA

Key Competitors

View All Competitors

Institutional Ownership

Prudential PLC
Sold 344,313 shares on 11/13/2023
Ownership: 7.502%

View All Institutional Transactions

PRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Prenetics Global stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRE shares.
View PRE analyst ratings or view top-rated stocks.
What is Prenetics Global's stock price target for 2024?: 1 Wall Street analysts have issued 1-year target prices for Prenetics Global's shares. Their PRE share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,328.6% from the stock's current price.
View analysts price targets for PRE or view top-rated stocks among Wall Street analysts.
How have PRE shares performed in 2023?: Prenetics Global's stock was trading at $30.00 at the beginning of 2023. Since then, PRE shares have decreased by 86.0% and is now trading at $4.20.
View the best growth stocks for 2023 here.
Are investors shorting Prenetics Global?: Prenetics Global saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 31,600 shares, a decline of 87.1% from the October 31st total of 245,600 shares. Based on an average daily trading volume, of 6,300 shares, the days-to-cover ratio is presently 5.0 days. Approximately 0.5% of the company's shares are sold short.
View Prenetics Global's Short Interest.
When is Prenetics Global's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our PRE earnings forecast.

How were Prenetics Global's earnings last quarter?: Prenetics Global Limited (NASDAQ:PRE) announced its quarterly earnings data on Friday, September, 15th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.15. The firm had revenue of $5.70 million for the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 3.89% and a negative net margin of 55.31%.
When did Prenetics Global's stock split?: Shares of Prenetics Global reverse split before market open on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
Who are Prenetics Global's major shareholders?: Prenetics Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Prudential PLC (7.50%).
How do I buy shares of Prenetics Global?: Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PRE) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial